AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

HCM · NASDAQ · Drug Manufacturers - Specialty & Generic

HUTCHMED (ADR)

Develops targeted therapies and immunotherapies, commercializing medicines in China and through global partners.

$12.31

After-hours close−0.06 (−0.49%)

At close$12.37(−0.36%)

Something off on this page? Send us feedback.

Profile

HUTCHMED (China) LimitedHCMHealth Care

Develops targeted therapies and immunotherapies for cancer and immunological diseases. It markets three internally developed medicines in China and uses partnerships to commercialize fruquintinib outside China.

Develops, manufactures, and markets targeted therapies and immunotherapies for cancer and immunological diseases. Its Oncology/Immunology business spans discovery through commercialization, while Other Ventures retains China prescription-drug and healthcare distribution activities.

In China, the internally developed medicines are Orpathys, Elunate, and Sulanda. Fruquintinib is marketed as Fruzaqla outside China through Takeda, while savolitinib is partnered with AstraZeneca.

The operating model combines in-house discovery and China commercialization with selected partners in markets outside China. Founded by a CK Hutchison subsidiary, it remains closely connected today to CK Hutchison through its largest shareholder.

Company facts

CEOJohnny Cheng

ListedMar 17, 2016

ExchangeNASDAQ

HeadquartersHong Kong, HK

CountryHong Kong

Employees1,799

CIK0001648257

ISINUS44842L1035

Key statistics

Market cap$2.16B

EPS (ttm)$0.1030

P/E (ttm)120.19

ROE1.4%

P/B1.74

P/S4.00

Dividend yield—

Beta0.64vs XLV 0.20

Year to date −9.4% · Average volume (30d) 58.2K

Analysts

Price target, next 12 months$13.80+11.5%Median of 10 analysts · vs the Aug 28 close

ConsensusBuy8 of 10 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $12.38

High$14.00+13.1%

Median$13.80+11.5%

Low$13.60+9.9%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Jul 23, 2026	Goldman Sachs	Reiterate		Neutral		$14
May 28, 2026	Morgan Stanley	Target			$17.50	$13.60
Sep 22, 2025	Morgan Stanley	Downgrade	Equal Weight	Underweight

Earnings

EPS

Estimate$0.15

Reported$0.05−68.3%

Revenue

Estimate$304.2M

Reported$278.3M−8.5%

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Jul 30, 2026Q2 FY26	$0.15	$0.05	−68.3%	$304.2M	$278.3M	−8.5%	−5.44%
Mar 5, 2026Q4 FY25	$2.50	—	—	$290.5M	$271.0M	−6.7%	0.00%
Aug 7, 2025Q2 FY25	$1.46	$1.30	−11.0%	$330.4M	$138.8M	−58.0%	−8.03%
Jul 2, 2025Q1 FY25	—	$1.30	—	—	$138.8M	—	+0.76%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$138.8M	$138.8M	$135.4M	$135.4M	$139.1M	$139.1M
Gross profit	$55.1M	$55.1M	−$23.1M	−$23.1M	$23.7M	$23.7M
Operating income	−$1.8M	−$1.8M	−$17.8M	−$17.8M	$434.5K	$434.5K
Net income	$227.5M	$227.5M	$977.5K	$977.5K	$8.0M	$8.0M
Diluted EPS	$1.30	$1.30	$0.01	$0.01	$0.05	$0.05
Gross margin	39.7%	39.7%	-17.1%	-17.1%	17.0%	17.0%
Operating margin	-1.3%	-1.3%	-13.2%	-13.2%	0.3%	0.3%

Fiscal years (4-quarter sums)FY21 $356.1M · FY22 $426.4M · FY23 $838.0M · FY24 $630.2M · FY25 $548.5M

Revenue by product · FY25

Other Collaboration Royalties Revenue$68.4M · 45%

Commercialization Services$45.3M · 29%

Collaboration Research And Development$27.9M · 18%

Other Collaboration Licensing Revenue$12.1M · 8%

Revenue by geography · FY25

China$407.5M · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $1.38B · Total debt $94.5M · Total assets $1.74B · Shareholders' equity $1.26B

Dividends

No dividends on record.

Ownership

Institutions 2.45%Insiders —

Shares outstanding 174.47M · Float 170.46M · 97.7% free float

Insiders — filings are in the shares behind the receipt.

This listing is a depositary receipt and the Form 4 positions here are filed in the shares behind it, a different unit from the share count and in a ratio the filings never state, so no insider percentage is shown.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Schroder Investment Management Group	1.48M	0.85%	13F	May 14, 2026
Allianz Asset Management GmbH	837.5K	0.48%	13F	May 11, 2026
State Street Corp	304.8K	0.17%	13F	May 15, 2026
Aia Group Ltd	291.2K	0.17%	13F	May 6, 2026
M&G PLC	255.5K	0.15%	13F	May 13, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.